Andra AP fonden Purchases Shares of 19,715 Solventum Co. (NYSE:SOLV)

Andra AP fonden purchased a new stake in Solventum Co. (NYSE:SOLV) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 19,715 shares of the company’s stock, valued at approximately $1,302,000.

Several other institutional investors and hedge funds also recently modified their holdings of SOLV. Trian Fund Management L.P. lifted its stake in shares of Solventum by 32.9% during the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after buying an additional 1,765,676 shares during the period. State Street Corp lifted its stake in shares of Solventum by 3.1% during the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after buying an additional 185,938 shares during the period. Geode Capital Management LLC lifted its stake in shares of Solventum by 4.0% during the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock valued at $232,608,000 after buying an additional 128,317 shares during the period. Hotchkis & Wiley Capital Management LLC purchased a new position in shares of Solventum during the third quarter valued at approximately $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Solventum by 0.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock valued at $73,469,000 after buying an additional 3,745 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. The Goldman Sachs Group upped their price target on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday, March 3rd. Morgan Stanley upped their price target on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. Piper Sandler upped their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Wells Fargo & Company upped their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. Finally, Bank of America upped their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $79.86.

Solventum Price Performance

Solventum stock opened at $77.96 on Monday. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The firm has a fifty day moving average of $73.65 and a 200-day moving average of $70.71. The firm has a market capitalization of $13.49 billion and a P/E ratio of 28.35. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.